Notice
Recent Posts
Recent Comments
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 |
Tags
- Malaysia
- Merger
- Japan
- LOI
- Japan Tobacco
- private equity
- buyout
- PEF
- cgi korea
- OTCBB
- Bank
- CA
- LOTTE
- acquisition
- Confidential Agreement
- capital gate
- China
- nda
- Acquistion
- securities
- sk
- Investment
- taiwan
- case study
- Letter of intent
- Korea M&A
- hong kong
- Korea
- China Construction Bank
- M&A
Archives
- Today
- Total
Korea M&A Corporation
GS’ acquisition of Hugel to change domestic BTX, bio markets
As the GS consortium is certain to acquire Korea's botulinum toxin (BTX) developer, Hugel, industry watchers are paying keen attention to how the acquisition would change the company and the domestic BTX and bio markets. The four-party private equity fund formed by the GS Group, also participated in by IMM Investment, China's CBC Group, and the United Arab Emirates (UAE) Mubadala Investment Comp..
News/M&A
2021. 8. 23. 10:23